Shan Riku Sakakibara Sells 8,000 Shares of Billiontoone (NASDAQ:BLLN) Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Shan Riku Sakakibara sold 8,000 shares of the firm’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $125.00, for a total transaction of $1,000,000.00. Following the transaction, the insider directly owned 204,000 shares of the company’s stock, valued at $25,500,000. The trade was a 3.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Shan Riku Sakakibara also recently made the following trade(s):

• On Wednesday, June 24th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The stock was sold at an average price of $110.00, for a total transaction of $880,000.00.
• On Monday, June 8th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The shares were sold at an average price of $98.22, for a total transaction of $785,760.00.

Billiontoone Trading Up 1.3%

Shares of Billiontoone stock opened at $124.87 on Wednesday. The firm has a market cap of $5.74 billion and a price-to-earnings ratio of 227.04. The business has a 50-day moving average price of $102.36 and a 200-day moving average price of $89.36. The company has a quick ratio of 10.58, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. Billiontoone, Inc. has a twelve month low of $61.96 and a twelve month high of $138.70.

Billiontoone (NASDAQ:BLLN) last posted its earnings results on Wednesday, May 6th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.33. The firm had revenue of $108.39 million during the quarter, compared to analysts’ expectations of $95.81 million. During the same quarter in the prior year, the firm posted ($0.39) earnings per share. Billiontoone’s quarterly revenue was up 83.8% on a year-over-year basis. Equities research analysts anticipate that Billiontoone, Inc. will post 0.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on BLLN shares. Weiss Ratings raised Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. BTIG Research reduced their price target on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. JPMorgan Chase & Co. upped their price target on shares of Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Finally, Guggenheim initiated coverage on shares of Billiontoone in a research report on Monday, June 29th. They set a “buy” rating and a $125.00 price objective for the company. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Billiontoone currently has a consensus rating of “Moderate Buy” and an average target price of $126.00.

Hedge Funds Weigh In On Billiontoone

Several large investors have recently modified their holdings of BLLN. Baillie Gifford & Co. purchased a new stake in shares of Billiontoone in the fourth quarter valued at $103,786,000. Massachusetts Financial Services Co. MA purchased a new position in shares of Billiontoone during the 4th quarter worth about $13,373,000. Emerald Mutual Fund Advisers Trust grew its holdings in Billiontoone by 11.9% during the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 132,206 shares of the company’s stock valued at $10,436,000 after purchasing an additional 14,072 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Billiontoone in the 4th quarter worth about $1,348,000. Finally, Emerald Advisers LLC lifted its stake in Billiontoone by 26.8% in the first quarter. Emerald Advisers LLC now owns 239,562 shares of the company’s stock worth $18,911,000 after purchasing an additional 50,613 shares during the last quarter.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.